Spots Global Cancer Trial Database for enzalutamide
Every month we try and update this database with for enzalutamide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer | NCT02522715 | Castration-Resi... Metastatic Pros... Recurrent Prost... Stage IV Prosta... | Cabazitaxel Enzalutamide Laboratory Biom... Pharmacological... Prednisone | 18 Years - | OHSU Knight Cancer Institute | |
| Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer | NCT02685267 | Prostate Cancer | Docetaxel Enzalutamide Prednisone | 18 Years - | Prostate Cancer Clinical Trials Consortium | |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | NCT06136624 | Prostate Cancer... | Opevesostat Abiraterone ace... Enzalutamide Hydrocortisone Fludrocortisone... Prednisone Dexamethasone | - | Merck Sharp & Dohme LLC | |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | NCT02960022 | Prostate Cancer | enzalutamide abiraterone ace... prednisone | 18 Years - | Astellas Pharma Inc | |
| A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely | NCT05202301 | Prostate Cancer | Darolutamide (N... Enzalutamide Apalutamide | 18 Years - | Bayer | |
| Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. | NCT05422911 | Metastatic Canc... Neoplasm, Prost... | Abiraterone ace... Apalutamide Enzalutamide | - | James J. Peters Veterans Affairs Medical Center | |
| Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) | NCT04332744 | Metastatic Pros... | Enzalutamide Talazoparib | 18 Years - | MedSIR | |
| a Vigibase Pharmacovigilance Study of ENzalutamide Drug-induced neurotoxicitY | NCT04290611 | Prostate Cancer Neuropathy Epilepsy Encephalopathy | Enzalutamide | 18 Years - 100 Years | Groupe Hospitalier Pitie-Salpetriere | |
| Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability | NCT02663193 | Prostate Cancer | No Intervention | 18 Years - | Janssen Scientific Affairs, LLC | |
| Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients | NCT01902251 | Prostate Cancer Pharmacokinetic... | Enzalutamide ta... Enzalutamide ca... | 18 Years - | Astellas Pharma Inc | |
| Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) | NCT02057939 | Prostate Cancer | enzalutamide Androgen Depriv... Radiation Thera... | 18 Years - | Duke University | |
| Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients | NCT03569280 | Castration-Resi... | Enzalutamide or... | 18 Years - | Kangpu Biopharmaceuticals, Ltd. | |
| A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 | NCT01534052 | Castration-Resi... | Enzalutamide | 18 Years - | Astellas Pharma Inc | |
| Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT05520138 | Prostatic Neopl... | Enzalutamide Abiraterone ace... | 18 Years - | Pfizer | |
| Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients | NCT03336983 | Prostate Cancer Bone Metastases | Zoledronic Acid Enzalutamide | 18 Years - | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | |
| Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer | NCT02430480 | Prostate Cancer | Goserelin Enzalutamide mpMRI | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | NCT04821622 | Prostate Cancer | talazoparib plu... Placebo plus en... | 18 Years - | Pfizer | |
| Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide | NCT01091103 | Metastatic Prog... | Enzalutamide | 18 Years - | Pfizer | |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) | NCT04191096 | Metastatic Horm... | Pembrolizumab Enzalutamide Androgen Depriv... Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer | NCT02254785 | Metastatic Cast... | cabazitaxel Abiraterone Enzalutamide 16... | 18 Years - | British Columbia Cancer Agency | |
| Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients | NCT02642913 | Hepatocellular ... | Enzalutamide Enzalutamide wi... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy | NCT02099864 | Castration-Resi... Metastatic Mali... Metastatic Mali... Metastatic Pros... Recurrent Prost... Stage III Prost... Stage IV Prosta... | Enzalutamide | 18 Years - | OHSU Knight Cancer Institute | |
| A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) | NCT02034552 | Prostatic Neopl... | Radium-223 dich... Abiraterone ace... Prednisone Enzalutamide | 18 Years - | Bayer | |
| Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | NCT04262154 | Metastatic Pros... | Atezolizumab Abiraterone Prednisone GnRH analog Stereotactic Bo... Enzalutamide Follow up | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer | NCT02446444 | Prostatic Neopl... | Enzalutamide Conventional NS... LHRHA External Beam R... | 18 Years - | University of Sydney | |
| Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer | NCT02685267 | Prostate Cancer | Docetaxel Enzalutamide Prednisone | 18 Years - | Prostate Cancer Clinical Trials Consortium | |
| Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | NCT04557449 | Liposarcoma CRC Prostate Cancer Breast Neoplasm... Adenocarcinoma ... Solid Tumors | PF-07220060 Letrozole Fulvestrant Midazolam Enzalutamide | 18 Years - | Pfizer | |
| Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer | NCT02918968 | Prostate Cancer | Enzalutamide Flutamide Androgen depriv... | 20 Years - | Astellas Pharma Inc | |
| Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel | NCT02491411 | Hormone-Resista... Metastatic Pros... Prostate Adenoc... Stage IV Prosta... | Dexamethasone Enzalutamide Laboratory Biom... Quality-of-Life... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer | NCT05818683 | Metastatic Cast... | JNJ-78278343 Cetrelimab Cabazitaxel Docetaxel Apalutamide Enzalutamide Darolutamide Abiraterone ace... | 18 Years - | Janssen Research & Development, LLC | |
| Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer | NCT05733351 | Castration-Sens... Metastatic Pros... Stage IVB Prost... | Abiraterone Biospecimen Col... Bone Scan Computed Tomogr... Docetaxel Enzalutamide FDG-Positron Em... Magnetic Resona... PSMA PET Scan Vudalimab | 18 Years - | Emory University | |
| Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer | NCT01889238 | Advanced, Andro... | Enzalutamide | 18 Years - | Pfizer | |
| A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide | NCT05901649 | Metastatic Horm... | Apalutamide Enzalutamide | 18 Years - | Janssen-Cilag Ltd. | |
| A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer | NCT04094519 | Prostate Cancer | enzalutamide enzalutamide Pl... digoxin rosuvastatin | 18 Years - | Astellas Pharma Inc | |
| Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer | NCT02685267 | Prostate Cancer | Docetaxel Enzalutamide Prednisone | 18 Years - | Prostate Cancer Clinical Trials Consortium | |
| An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) | NCT05112965 | Neoplasms | Atezolizumab Bevacizumab Pemetrexed Paclitaxel Enzalutamide | 18 Years - | Hoffmann-La Roche | |
| Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) | NCT02987543 | Metastatic Cast... | olaparib enzalutamide abiraterone ace... abiraterone ace... enzalutamide | 18 Years - 130 Years | AstraZeneca | |
| Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer | NCT06228053 | Metastatic Cast... | SX-682 Enzalutamide | 18 Years - | Syntrix Biosystems, Inc. | |
| Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide | NCT04335682 | Metastatic Pros... Prostate Cancer... Prostate Cancer Castrate Resist... | Darolutamide Enzalutamide | 18 Years - | Alliance Foundation Trials, LLC. | |
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | NCT05191017 | Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration Resi... Castration Resi... | NUV-422 Enzalutamide | 18 Years - | Nuvation Bio Inc. | |
| Enzalutamide Implants (Enolen) in Patients With Prostate Cancer | NCT06257693 | Prostate Adenoc... | enzalutamide | 21 Years - | Alessa Therapeutics Inc. | |
| A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer | NCT01981122 | Metastatic Pros... | sipuleucel-T enzalutamide | 18 Years - | Dendreon | |
| A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | NCT05849298 | Prostatic Neopl... | AAA617 AAA517 Piflufolastat F... ARPI ADT Best supportive... | 18 Years - | Novartis | |
| Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment | NCT04647526 | Metastatic Cast... | [Lu-177]-PNT200... Abiraterone Enzalutamide | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation | NCT03297385 | Prostate Cancer DNA Androgen Recept... | Enzalutamide | 18 Years - | The Netherlands Cancer Institute | |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension | NCT04934722 | Metastatic Horm... | Pembrolizumab Enzalutamide Androgen Depriv... Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | NCT05849298 | Prostatic Neopl... | AAA617 AAA517 Piflufolastat F... ARPI ADT Best supportive... | 18 Years - | Novartis | |
| Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers | NCT02749903 | Salivary Cancer | enzalutamide | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer | NCT02207504 | Castration-resi... | Crizotinib Enzalutamide | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) | NCT03834519 | Prostatic Neopl... | Pembrolizumab Olaparib Abiraterone ace... Prednisone Enzalutamide Prednisolone | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | NCT02960022 | Prostate Cancer | enzalutamide abiraterone ace... prednisone | 18 Years - | Astellas Pharma Inc | |
| A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | NCT02124668 | Castration-Resi... Prostate Cancer | Enzalutamide | - | Astellas Pharma Inc | |
| A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer | NCT01981122 | Metastatic Pros... | sipuleucel-T enzalutamide | 18 Years - | Dendreon | |
| Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC) | NCT04157088 | Prostatic Cance... | Darolutamide (N... Enzalutamide | 18 Years - | Bayer | |
| A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer | NCT01288911 | Prostatic Neopl... | enzalutamide bicalutamide | 18 Years - | Astellas Pharma Inc | |
| Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer | NCT02833883 | Prostate Cancer Castration Resi... | Enzalutamide CC-115 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide | NCT01091103 | Metastatic Prog... | Enzalutamide | 18 Years - | Pfizer | |
| Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression | NCT02555189 | Castration-Resi... Metastatic Pros... Prostate Carcin... Stage IV Prosta... | Enzalutamide Ribociclib Laboratory Biom... Pharmacological... Biospecimen Col... Biopsy Echocardiograph... Multigated Acqu... Bone Scan Computed Tomogr... Magnetic Resona... | 18 Years - | Thomas Jefferson University | |
| Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol | NCT04145375 | mCRPC | ZEN003694 Enzalutamide | 18 Years - | Zenith Epigenetics | |
| Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer | NCT05037500 | Castration-Resi... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Decitabine and ... Enzalutamide | 18 Years - | Roswell Park Cancer Institute | |
| Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer | NCT01565928 | Prostate Cancer | MDV3100 | 18 Years - | Pfizer | |
| Evaluation of Fapi-pet in Prostate Cancer. | NCT05192694 | Prostate Cancer | Computed tomogr... | 18 Years - 100 Years | Helsinki University Central Hospital | |
| A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide | NCT05901649 | Metastatic Horm... | Apalutamide Enzalutamide | 18 Years - | Janssen-Cilag Ltd. | |
| Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | NCT06430411 | Prostate Cancer... Prostate Cancer... Prostate Cancer Prostate Neopla... Oligometastatic... Oligometastasis | Radical prostat... Prostate irradi... Surgical metast... Irradiation of ... Abiraterone ace... Enzalutamide Darolutamide Apalutamide Docetaxel Lutetium-PSMA Androgen depriv... | 18 Years - 80 Years | Medical University of Vienna | |
| Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | NCT02446405 | Prostatic Neopl... | Enzalutamide NSAA LHRHA or Surgic... | 18 Years - | University of Sydney | |
| A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden | NCT03328364 | Metastatic Cast... | enzalutamide docetaxel | 18 Years - | Astellas Pharma Inc | |
| Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | NCT02319837 | Hormone Sensiti... Prostate Cancer Cancer of the P... | Enzalutamide Placebo (No lon... Leuprolide Open... | 18 Years - | Pfizer | |
| A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer | NCT04087174 | Prostate Cancer | Capivasertib Enzalutamide Abiraterone | 18 Years - 130 Years | AstraZeneca | |
| Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | NCT05701007 | Metastatic Cast... Metastatic Cast... | abiraterone enzalutamide docetaxel apalutamide cabazitaxel Radium-223 Lutetium-177 degarelix goserelin leuprorelin triptorelin | 18 Years - | Pfizer | |
| A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer | NCT01212991 | Prostate Cancer | Enzalutamide Placebo | 18 Years - | Pfizer | |
| Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases | NCT02758132 | Prostate Cancer | Denosumab Enzalutamide Abiraterone Prednisone | 18 Years - | University of Hawaii | |
| Duration of Enzalutamide and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT) | NCT05404139 | Metastatic Pros... | Enzalutamide Standard of Car... | 18 Years - 100 Years | University Health Network, Toronto | |
| Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy. | NCT02346578 | Castration-resi... | Enzalutamide Flutamide | 20 Years - | Osaka City University | |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | NCT02960022 | Prostate Cancer | enzalutamide abiraterone ace... prednisone | 18 Years - | Astellas Pharma Inc | |
| An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings | NCT05362149 | Non-metastatic ... | Darolutamide (N... Enzalutamide Apalutamide | 18 Years - | Bayer | |
| A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | NCT06072196 | Prostatic Neopl... | Novel hormonal ... | 65 Years - | Pfizer | |
| Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer | NCT05212857 | Prostate Cancer | Leuprolide acet... Goserelin aceta... Triptorelin ace... Degarelix aceta... Abiraterone ace... Apalutamide Enzalutamide Local treatment... Radiotherapy fo... Radiotherapy fo... | 18 Years - 80 Years | Fudan University | |
| Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) | NCT03834493 | Prostatic Neopl... | Pembrolizumab Enzalutamide Placebo | 18 Years - | Merck Sharp & Dohme LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
